Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem

Title:Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem

Volume: 17 Issue: 2

Author(s): Suresh J. Antony*Leigh G. Cooper

Affiliation:

• 1205 N. Oregon, El Paso, Texas 79902,United States

Keywords: Oritavancin, prosthetic joint, intravenous, lipoglycopeptide, Morbidity, lipoglycopeptide.

Abstract: Prosthetic joint infections (PJI) result in significant morbidity, mortality and cost to patients and the health system. Traditional treatment involves a twostaged revision and occasionally a single staged revision along with intravenous antibiotics (IV) and or oral antibiotics for several weeks to months. The use of a single staged revision along with an antibiotic which has a prolonged half life and is bactericidal would be ideal. We present 2 patients who were treated successfully with a single stage revision/antibiotic spacer and a new novel long acting lipoglycopeptide called oritavancin.

Cite this article as:

Antony J. Suresh*, Cooper G. Leigh, Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem, Infectious Disorders - Drug Targets 2017; 17 (2) . https://dx.doi.org/10.2174/1871526517666161108130148